ocr: Figure 1 COMPARISON TO IBUPROFEN Life-Table Cumulative Incidence Rate of Gastroduodenal Ulcers 2 3mm** (Intention-to-Treat) 50 U.S. Study 45.8 a 40 1 - 30 27.7 20 18.8 14.71 a 10 9.91 7.31 9.6T 3.4 2.9 4.7 6-Week 12-Week*** 24-Week Time by Treatment - Placebo (N=158) Rofecoxib 25mg (N=186) Rofecoxib 50mg (N=178) Ibuprofen 2400 mg (N=167) p<0.001 versus ibuprofen 2400 mg - * Results of analyses using a 2 5mm gastroduodenal ulcer endpoint were consistent. *** The primary endpoint was the cumulative incidence of gastroduodenal ulcer at 12 weeks.
